{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T17:32:53Z","timestamp":1781285573286,"version":"3.54.1"},"reference-count":80,"publisher":"Hindawi Limited","issue":"4","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":463,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast J"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1111\/tbj.12278","type":"journal-article","created":{"date-parts":[[2014,5,26]],"date-time":"2014-05-26T06:58:41Z","timestamp":1401087521000},"page":"347-357","source":"Crossref","is-referenced-by-count":6,"title":["Managing Postmenopausal Women with Hormone Receptor-Positive Advanced Breast Cancer Who Progress on Endocrine Therapies with Inhibitors of the PI3K Pathway"],"prefix":"10.1155","volume":"20","author":[{"given":"Adam M.","family":"Brufsky","sequence":"first","affiliation":[{"name":"Magee-Women's Hospital; University of Pittsburgh School of Medicine; Pittsburgh Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"98","published-online":{"date-parts":[[2014,5,26]]},"reference":[{"key":"10.1111\/tbj.12278-BIB0001|tbj12278-cit-0001","first-page":"1","volume-title":"Cancer Facts and Figures 2012","author":"American Cancer Society","year":"2012"},{"key":"10.1111\/tbj.12278-BIB0002|tbj12278-cit-0002","first-page":"1","volume-title":"Breast Cancer Facts and Figures: 2011-2012","author":"American Cancer Society","year":"2012"},{"key":"10.1111\/tbj.12278-BIB0003|tbj12278-cit-0003","unstructured":"National Cancer Institute SEER Statistic Fact Sheet: Breast Cancer 2013 http:\/\/seer.cancer.gov\/statfacts\/html\/breast.html"},{"key":"10.1111\/tbj.12278-BIB0004|tbj12278-cit-0004","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1093\/aje\/kwp036","article-title":"Breast cancer risk factors defined by estrogen and progesterone receptor status: the multiethnic cohort study","volume":"169","author":"Setiawan","year":"2009","journal-title":"Am J Epidemiol"},{"key":"10.1111\/tbj.12278-BIB0005|tbj12278-cit-0005","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1007\/s10147-011-0215-5","article-title":"High estrogen receptor expression and low Ki67 expression are associated with improved time to progression during first-line endocrine therapy with aromatase inhibitors in breast cancer","volume":"16","author":"Endo","year":"2011","journal-title":"Int J Clin Oncol"},{"key":"10.1111\/tbj.12278-BIB0006|tbj12278-cit-0006","unstructured":"National Comprehensive Cancer Network, Inc NCCN Clinical Practice Guidelines in Oncology http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf"},{"key":"10.1111\/tbj.12278-BIB0007|tbj12278-cit-0007","first-page":"CD003370","article-title":"Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women","author":"Gibson","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1111\/tbj.12278-BIB0008|tbj12278-cit-0008","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1002\/1097-0142(20011101)92:9<2247::AID-CNCR1570>3.0.CO;2-Y","article-title":"Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma","volume":"92","author":"Bonneterre","year":"2001","journal-title":"Cancer"},{"key":"10.1111\/tbj.12278-BIB0009|tbj12278-cit-0009","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1200\/JCO.2001.19.10.2596","article-title":"Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group","volume":"19","author":"Mouridsen","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1111\/tbj.12278-BIB0010|tbj12278-cit-0010","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1200\/JCO.2003.04.194","article-title":"Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group","volume":"21","author":"Mouridsen","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1111\/tbj.12278-BIB0011|tbj12278-cit-0011","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/COC.0b013e31819fdf9b","article-title":"Exemestane as first-line therapy in postmenopausal women with recurrent or metastatic breast cancer","volume":"33","author":"Gluck","year":"2010","journal-title":"Am J Clin Oncol"},{"key":"10.1111\/tbj.12278-BIB0012|tbj12278-cit-0012","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s10549-010-0974-0","article-title":"Systematic review of aromatase inhibitors in the first-line treatment for hormone sensitive advanced or metastatic breast cancer","volume":"123","author":"Riemsma","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"10.1111\/tbj.12278-BIB0013|tbj12278-cit-0013","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1093\/jnci\/djj357","article-title":"Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis","volume":"98","author":"Mauri","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"10.1111\/tbj.12278-BIB0014|tbj12278-cit-0014","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S0140-6736(12)61963-1","article-title":"Long-term eff ects of continuing adjuvant tamoxifen to 10\u00a0years versus stopping at 5\u00a0years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial","volume":"381","author":"Davies","year":"2013","journal-title":"Lancet"},{"key":"10.1111\/tbj.12278-BIB0015|tbj12278-cit-0015","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1586\/14737140.9.2.187","article-title":"Endocrine therapy for the treatment of postmenopausal women with breast cancer","volume":"9","author":"Harichand-Herdt","year":"2009","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1111\/tbj.12278-BIB0016|tbj12278-cit-0016","first-page":"CD008926","article-title":"Toremifene versus tamoxifen for advanced breast cancer","volume":"7","author":"Mao","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1111\/tbj.12278-BIB0017|tbj12278-cit-0017","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1517\/14740338.2011.595560","article-title":"Emerging data on the efficacy and safety of fulvestrant, a unique antiestrogen therapy for advanced breast cancer","volume":"10","author":"Scott","year":"2011","journal-title":"Expert Opin Drug Saf"},{"key":"10.1111\/tbj.12278-BIB0018|tbj12278-cit-0018","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1200\/JCO.2004.02.112","article-title":"Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial","volume":"22","author":"Howell","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1111\/tbj.12278-BIB0019|tbj12278-cit-0019","doi-asserted-by":"crossref","first-page":"4530","DOI":"10.1200\/JCO.2008.21.1136","article-title":"Activity of fulvestrant 500\u00a0mg versus anastrozole 1\u00a0mg as first-line treatment for advanced breast cancer: results from the FIRST study","volume":"27","author":"Robertson","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1111\/tbj.12278-BIB0020|tbj12278-cit-0020","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1200\/JCO.2002.10.058","article-title":"Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial","volume":"20","author":"Osborne","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1111\/tbj.12278-BIB0021|tbj12278-cit-0021","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.1200\/JCO.2002.10.057","article-title":"Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment","volume":"20","author":"Howell","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1111\/tbj.12278-BIB0022|tbj12278-cit-0022","doi-asserted-by":"crossref","first-page":"djt337","DOI":"10.1093\/jnci\/djt337","article-title":"Final Overall Survival: Fulvestrant 500 mg vs 250 mg in the Randomized CONFIRM Trial","volume":"106","author":"Di","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"10.1111\/tbj.12278-BIB0023|tbj12278-cit-0023","unstructured":"Faslodex\u00ae 2004"},{"key":"10.1111\/tbj.12278-BIB0024|tbj12278-cit-0024","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/nrc2713","article-title":"Biological determinants of endocrine resistance in breast cancer","volume":"9","author":"Musgrove","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"10.1111\/tbj.12278-BIB0025|tbj12278-cit-0025","doi-asserted-by":"crossref","first-page":"5439","DOI":"10.1158\/0008-5472.CAN-04-2782","article-title":"Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model","volume":"65","author":"Jelovac","year":"2005","journal-title":"Cancer Res"},{"key":"10.1111\/tbj.12278-BIB0026|tbj12278-cit-0026","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1158\/0008-5472.CAN-07-6807","article-title":"Combination of anastrozole with fulvestrant in the intratumoral aromatase xenograft model","volume":"68","author":"Macedo","year":"2008","journal-title":"Cancer Res"},{"key":"10.1111\/tbj.12278-BIB0027|tbj12278-cit-0027","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1056\/NEJMoa1201622","article-title":"Combination anastrozole and fulvestrant in metastatic breast cancer","volume":"367","author":"Mehta","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1111\/tbj.12278-BIB0028|tbj12278-cit-0028","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1200\/JCO.2011.38.1095","article-title":"FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer","volume":"30","author":"Bergh","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1111\/tbj.12278-BIB0029|tbj12278-cit-0029","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S1470-2045(13)70322-X","article-title":"Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial","volume":"14","author":"Johnston","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1111\/tbj.12278-BIB0030|tbj12278-cit-0030","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s10549-011-1513-3","article-title":"KX-01, a novel Src kinase inhibitor directed toward the peptide substrate site, synergizes with tamoxifen in estrogen receptor alpha positive breast cancer","volume":"132","author":"Anbalagan","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1111\/tbj.12278-BIB0031|tbj12278-cit-0031","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1093\/annonc\/mds240","article-title":"Enhanced expression of the PDGFR\/Abl signaling pathway in aromatase inhibitor-resistant breast cancer","volume":"24","author":"Weigel","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1111\/tbj.12278-BIB0032|tbj12278-cit-0032","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S1470-2045(13)70026-3","article-title":"Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial","volume":"14","author":"Robertson","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1111\/tbj.12278-BIB0033|tbj12278-cit-0033","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1093\/annonc\/mdn689","article-title":"Phase II trial of the farnesyltransferase inhibitor tipifarnib plus fulvestrant in hormone receptor-positive metastatic breast cancer: New York Cancer Consortium Trial P6205","volume":"20","author":"Li","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1111\/tbj.12278-BIB0034|tbj12278-cit-0034","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1038\/bjc.2011.156","article-title":"A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer","volume":"104","author":"Munster","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1111\/tbj.12278-BIB0035|tbj12278-cit-0035","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1200\/JCO.2012.43.7251","article-title":"Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor","volume":"31","author":"Yardley","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1111\/tbj.12278-BIB0036|tbj12278-cit-0036","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1158\/1078-0432.CCR-09-2282","article-title":"Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer","volume":"16","author":"Cristofanilli","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1111\/tbj.12278-BIB0037|tbj12278-cit-0037","doi-asserted-by":"crossref","first-page":"R77","DOI":"10.1186\/bcr2419","article-title":"PD 0332991, a selective cyclin D kinase 4\/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro","volume":"11","author":"Finn","year":"2009","journal-title":"Breast Cancer Res"},{"key":"10.1111\/tbj.12278-BIB0038|tbj12278-cit-0038","doi-asserted-by":"crossref","first-page":"ii43","DOI":"10.1093\/annonc\/mds045","article-title":"Results of a randomized phase 2 study of PD0332991, a cyclin-dependent kinase (CDK) 4\/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+HER2- advanced breast cancer(BC)","volume":"23","author":"Finn","year":"2012","journal-title":"Ann Oncol"},{"issue":"suppl 3","key":"10.1111\/tbj.12278-BIB0039|tbj12278-cit-0039","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.3816\/CBC.2010.s.016","article-title":"Targeting endocrine resistance: is there a role for mTOR inhibition?","volume":"10","author":"Sheri","year":"2010","journal-title":"Clin Breast Cancer"},{"key":"10.1111\/tbj.12278-BIB0040|tbj12278-cit-0040","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1158\/1078-0432.CCR-09-1823","article-title":"New strategies in estrogen receptor-positive breast cancer","volume":"16","author":"Johnston","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1111\/tbj.12278-BIB0041|tbj12278-cit-0041","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1158\/0008-5472-CAN-04-3913","article-title":"PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma","volume":"65","author":"Saal","year":"2005","journal-title":"Cancer Res"},{"key":"10.1111\/tbj.12278-BIB0042|tbj12278-cit-0042","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.4161\/cc.3.10.1164","article-title":"Oncogenic mutations of PIK3CA in human cancers","volume":"3","author":"Samuels","year":"2004","journal-title":"Cell Cycle"},{"key":"10.1111\/tbj.12278-BIB0043|tbj12278-cit-0043","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1172\/JCI41680","article-title":"Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer","volume":"120","author":"Miller","year":"2010","journal-title":"J Clin Invest"},{"key":"10.1111\/tbj.12278-BIB0044|tbj12278-cit-0044","doi-asserted-by":"crossref","first-page":"8059","DOI":"10.1158\/1078-0432.CCR-04-0035","article-title":"Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity","volume":"10","author":"deGraffenried","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1111\/tbj.12278-BIB0045|tbj12278-cit-0045","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/sj.bjc.6600126","article-title":"Activation of AKT\/PKB in breast cancer predicts a worse outcome among endocrine treated patients","volume":"86","author":"Perez-Tenorio","year":"2002","journal-title":"Br J Cancer"},{"key":"10.1111\/tbj.12278-BIB0046|tbj12278-cit-0046","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1093\/annonc\/mdm170","article-title":"Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling","volume":"18","author":"Beeram","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1111\/tbj.12278-BIB0047|tbj12278-cit-0047","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s10549-010-0986-9","article-title":"\u201cOvercoming breast cancer drug resistance with mTOR inhibitors\u201d. Could it be a myth or a real possibility in the short-term future?","volume":"128","author":"Margariti","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"10.1111\/tbj.12278-BIB0048|tbj12278-cit-0048","doi-asserted-by":"crossref","unstructured":"Bhattacharyya GN Biswas J Singh JH et\u00a0al Reversal of tamoxifen resistance (hormone resistance) by addition of sirolimus (mTOR inhibitor) in metastatic breast cancer 2011 Stockholm, Sweden","DOI":"10.1016\/S0959-8049(11)70115-0"},{"key":"10.1111\/tbj.12278-BIB0049|tbj12278-cit-0049","doi-asserted-by":"crossref","unstructured":"Carpenter J Roche H Campone M et\u00a0al Randomized 3-arm, phase 2 study of temsirolimus (CCI-779) in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer 2005 Orlando, FL","DOI":"10.1200\/jco.2005.23.16_suppl.564"},{"key":"10.1111\/tbj.12278-BIB0050|tbj12278-cit-0050","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1200\/JCO.2011.38.3331","article-title":"Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer","volume":"31","author":"Wolff","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1111\/tbj.12278-BIB0051|tbj12278-cit-0051","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ejca.2007.10.003","article-title":"The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics","volume":"44","author":"Awada","year":"2008","journal-title":"Eur J Cancer"},{"key":"10.1111\/tbj.12278-BIB0052|tbj12278-cit-0052","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1200\/JCO.2011.39.0708","article-title":"Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study","volume":"30","author":"Bachelot","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1111\/tbj.12278-BIB0053|tbj12278-cit-0053","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1109653","article-title":"Everolimus in postmenopausal hormone receptor-positive advanced breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1111\/tbj.12278-BIB0054|tbj12278-cit-0054","doi-asserted-by":"crossref","unstructured":"Safra T Kaufman B Evron E et\u00a0al RAD001 (Everolimus) in combination with Letrozole in the treatment of postmenopausal women with estrogen receptor positive Metastatic Breast cancer after failure of hormonal therapy - a phase II study 2012 San Antonio, TX","DOI":"10.1158\/0008-5472.SABCS12-P5-20-06"},{"key":"10.1111\/tbj.12278-BIB0055|tbj12278-cit-0055","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s10549-013-2810-9","article-title":"A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure","volume":"143","author":"Massarweh","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"10.1111\/tbj.12278-BIB0056|tbj12278-cit-0056","doi-asserted-by":"crossref","unstructured":"Hortobagyi GN Piccart M Rugo H et\u00a0al Everolimus for postmenopausal women with advanced breast cancer: updated results of the BOLERO 2 phase III trial 2011 San Antonio, TX","DOI":"10.1158\/0008-5472.SABCS11-S3-7"},{"key":"10.1111\/tbj.12278-BIB0057|tbj12278-cit-0057","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1007\/s12325-013-0060-1","article-title":"Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis","volume":"30","author":"Yardley","year":"2013","journal-title":"Adv Ther"},{"key":"10.1111\/tbj.12278-BIB0058|tbj12278-cit-0058","doi-asserted-by":"crossref","unstructured":"Piccart M Baselga J Noguchi S et\u00a0al Final progression-free survival analysis of BOLERO-2: a phase III trial of everolimus for postmenopausal women with advanced breast cancer 2012 San Antonio, TX","DOI":"10.1158\/0008-5472.SABCS12-P6-04-02"},{"key":"10.1111\/tbj.12278-BIB0059|tbj12278-cit-0059","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.clbc.2013.08.011","article-title":"Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2","volume":"13","author":"Pritchard","year":"2013","journal-title":"Clin Breast Cancer"},{"key":"10.1111\/tbj.12278-BIB0060|tbj12278-cit-0060","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1016\/j.ejca.2013.04.011","article-title":"Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 study","volume":"49","author":"Campone","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1111\/tbj.12278-BIB0061|tbj12278-cit-0061","doi-asserted-by":"crossref","DOI":"10.1007\/s12282-013-0444-8","article-title":"Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2 [published online ahead of print February 13, 2013]","author":"Noguchi","year":"2013","journal-title":"Breast Cancer"},{"key":"10.1111\/tbj.12278-BIB0062|tbj12278-cit-0062","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1002\/cncr.28010","article-title":"Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial","volume":"119","author":"Burris","year":"2013","journal-title":"Cancer"},{"key":"10.1111\/tbj.12278-BIB0063|tbj12278-cit-0063","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1185\/03007995.2013.836078","article-title":"Health-related quality of life and disease symptoms in postmenopausal women with HR+, HER2- advanced breast cancer treated witheverolimus plus exemestane versus exemestane monotherapy [published online ahead of print September 4, 2013]","volume":"29","author":"Campone","year":"2013","journal-title":"Curr Med Res Opin"},{"key":"10.1111\/tbj.12278-BIB0064|tbj12278-cit-0064","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1210\/jc.2010-1679","article-title":"Clinical review: effect of endocrine therapies on bone in breast cancer patients","volume":"96","author":"Santen","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1111\/tbj.12278-BIB0065|tbj12278-cit-0065","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1093\/jnci\/djt026","article-title":"Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2","volume":"105","author":"Gnant","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"10.1111\/tbj.12278-BIB0066|tbj12278-cit-0066","doi-asserted-by":"crossref","unstructured":"Chavez-Macgregor M Barlow WE Gonzalez-Angulo AM et\u00a0al A phase III randomized, placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy +\/- one year of everolimus in patients with high-risk 2012 San Antonio, TX","DOI":"10.1158\/0008-5472.SABCS12-OT2-2-04"},{"key":"10.1111\/tbj.12278-BIB0067|tbj12278-cit-0067","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1158\/1535-7163.MCT-11-0474","article-title":"Identification and Characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor","volume":"11","author":"Maira","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"10.1111\/tbj.12278-BIB0068|tbj12278-cit-0068","doi-asserted-by":"crossref","unstructured":"di Leo A Germa C Weber D et\u00a0al Phase III randomized study of the oral pan.PI3K inhibitor BKM120 with fulvestrant in postmenopausal women with HR+\/HER2- locally advanced or metastatic breast cancer, treated with aromatase inhibitor, and progressed on or after mTOR inhibitor.based treatment - BELLE.3 2012 San Antonio, TX","DOI":"10.1158\/0008-5472.SABCS12-OT2-3-08"},{"key":"10.1111\/tbj.12278-BIB0069|tbj12278-cit-0069","doi-asserted-by":"crossref","first-page":"5816","DOI":"10.1158\/1078-0432.CCR-12-1141","article-title":"Biomarkers of response to Akt inhibitor MK-2206 in breast cancer","volume":"18","author":"Sangai","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1111\/tbj.12278-BIB0070|tbj12278-cit-0070","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1158\/1535-7163.MCT-08-0017","article-title":"Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase\/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity","volume":"7","author":"Maira","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"10.1111\/tbj.12278-BIB0071|tbj12278-cit-0071","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1016\/j.ejca.2012.06.027","article-title":"Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K\/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies","volume":"48","author":"Mahadevan","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1111\/tbj.12278-BIB0072|tbj12278-cit-0072","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-13-2403","article-title":"Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K\/mTOR inhibitor in patients with advanced solid tumors","author":"Papadopoulos","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1111\/tbj.12278-BIB0073|tbj12278-cit-0073","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/nrc2664","article-title":"Targeting PI3K signalling in cancer: opportunities, challenges and limitations","volume":"9","author":"Engelman","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"10.1111\/tbj.12278-BIB0074|tbj12278-cit-0074","doi-asserted-by":"crossref","first-page":"7116","DOI":"10.1158\/1078-0432.CCR-11-0796","article-title":"Novel phosphoinositide 3-kinase\/mTOR dual inhibitor, NVP-BGT226, displays potent growth-inhibitory activity against human head and neck cancer cells in vitro and in vivo","volume":"17","author":"Chang","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1111\/tbj.12278-BIB0075|tbj12278-cit-0075","doi-asserted-by":"crossref","first-page":"R21","DOI":"10.1186\/bcr2833","article-title":"Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer","volume":"13","author":"Sanchez","year":"2011","journal-title":"Breast Cancer Res"},{"key":"10.1111\/tbj.12278-BIB0076|tbj12278-cit-0076","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1093\/annonc\/mds011","article-title":"Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors","volume":"23","author":"Markman","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1111\/tbj.12278-BIB0077|tbj12278-cit-0077","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1158\/1535-7163.MCT-11-0446","article-title":"GDC-0980 is a novel class I PI3K\/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway","volume":"10","author":"Wallin","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"10.1111\/tbj.12278-BIB0078|tbj12278-cit-0078","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1038\/leu.2010.170","article-title":"Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies","volume":"24","author":"Chapuis","year":"2010","journal-title":"Leukemia"},{"key":"10.1111\/tbj.12278-BIB0079|tbj12278-cit-0079","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nm.2091","article-title":"Effective and selective targeting of leukemia cells using a TORC1\/2 kinase inhibitor","volume":"16","author":"Janes","year":"2010","journal-title":"Nat Med"},{"key":"10.1111\/tbj.12278-BIB0080|tbj12278-cit-0080","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1002\/ijc.25116","article-title":"Selective concomitant inhibition of mTORC1 and mTORC2 activity in estrogen receptor negative breast cancer cells by BN107 and oleanolic acid","volume":"127","author":"Chu","year":"2010","journal-title":"Int J Cancer"}],"container-title":["The Breast Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Ftbj.12278","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/tbj.12278\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T18:22:43Z","timestamp":1649096563000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/tbj.12278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,26]]},"references-count":80,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,7]]}},"URL":"https:\/\/doi.org\/10.1111\/tbj.12278","relation":{},"ISSN":["1075-122X"],"issn-type":[{"value":"1075-122X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5,26]]}}}